I’m a seasoned clinical research professional with over two decades of experience supporting and leading clinical trials across all phases and therapeutic areas. My journey has taken me through top pharmaceutical organizations like Bristol Myers Squibb, GSK, Karuna Therapeutics, and AstraZeneca, where I’ve specialized in clinical operations, regulatory compliance, and team development. I’m passionate about building efficient systems, mentoring others, and contributing to work that ultimately improves patient lives.

I'm a biotech executive and scientist with a passion for advancing oncology therapeutics from discovery through clinical development. Over the course of my career, I’ve led R\&D strategy and operations in organizations ranging from early-stage startups to large global pharma, including Takeda, ImmunoGen, Novartis, and Biogen. I’ve had the privilege of building high-performing teams, guiding complex portfolios, and contributing to therapies that make a real difference for patients. Today, I enjoy advising innovative biotech companies and VCs as they shape the next generation of cancer treatments.

Susan Essumang is a seasoned clinical operations executive who merges scientific rigor with strategic leadership to drive high-impact pharmaceutical and biotech programs. Known for her patient-centric approach, Susan has led the development and regulatory success of globally recognized treatments, including Victoza®, Ozempic®, and Wegovy®, delivering billions in projected revenue. Her ability to align enterprise objectives with operational excellence has resulted in accelerated trial timelines, significant cost savings, and flawless regulatory inspections. With deep therapeutic expertise, a foundation in neuroscience and healthcare administration, and a commitment to innovation, Susan continues to shape the future of clinical research through data-driven insights and strategic execution.

I’m excited to share a professional biography that reflects my journey across the biotech and pharma industries—from hands-on research to strategic leadership. It's been a privilege to work with exceptional teams, lead impactful projects, and help bring new therapies closer to the patients who need them most.

I'm excited to share my professional biography, capturing the journey I've taken across HEOR, pharmaceutical innovation, real-world evidence, and health policy. With over 20 years of experience in building value through data, strategic insight, and collaborative leadership, I'm proud to continue this work alongside inspiring teams and partners.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Dr. Larrye Ellis Loss, PharmD, MBA, is a global pharmaceutical executive and consultant with over 40 years of experience leading clinical development, medical affairs, and strategic operations across the life sciences industry. With a distinguished career at AstraZeneca and current advisory work through his own consultancy, Larrye brings deep expertise in drug development, regulatory strategy, and cross-functional leadership. He is known for his integrity, global perspective, and commitment to mentoring the next generation of healthcare professionals. Passionate about service, he also dedicates his time to nonprofit leadership and disaster relief with the American Red Cross.

After over 40 years of experience in pharmacy, biotech, and medical affairs, I’m excited to share my professional biography that reflects my journey from clinical care to corporate strategy, mentorship, and innovation. Whether supporting startups or collaborating with global medical societies, I’ve always been driven by the desire to connect science with purpose. Here is my biography.

Thrilled to share my professional biography, which captures the arc of my 30+ year journey across life sciences, innovation, strategy, and global health. I’ve had the honor of collaborating with visionary leaders and organizations to unlock transformative value at the intersection of science, business, and impact.

I am excited to share my executive biography, highlighting my journey in oncology, clinical research, and medical affairs over the past 25 years. From my work as a medical science liaison to my leadership in pharmacy education and healthcare consulting, I have been committed to advancing patient care, scientific innovation, and medical education. If you're interested in learning more about my background, expertise, and contributions to pharmaceutical sciences and healthcare strategy.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Excited to share my professional executive biography! With over 20 years of experience in biotech program management, drug development, and regulatory strategy, I have had the privilege of leading cross-functional teams, guiding early-stage startups, and ensuring successful clinical execution. If you're looking for strategic leadership, operational excellence, and industry expertise, I’d love to connect and explore opportunities to collaborate.

Raymond Chang is a seasoned Translational Imaging Scientist with over two decades of experience spanning pharmaceutical research, contract research organizations, and academic discovery. Renowned for his expertise in advanced imaging modalities such as PET, SPECT, and CT, Chang has contributed significantly to the development of preclinical disease models and innovative therapeutics. His career highlights include leading the enterprise implementation of multimodality bioinformatics systems, developing cutting-edge imaging tools, and managing GLP and Non-GLP studies that bridge preclinical and clinical research. A dedicated leader and collaborator, Chang excels in regulatory compliance, experimental design, and fostering partnerships, making him a pivotal figure in advancing personalized medicine and imaging science.

The healthcare investment landscape is undergoing a revolutionary transformation, addressing the binary risk and inefficiency that have long plagued therapeutic R&D. Traditional drug development processes are slow, costly, and fraught with failure, but advances in AI are now enabling faster, more accurate drug discovery and validation. Leveraging this potential, a novel funding model has emerged, combining insurance underwriting by Lloyd’s of London and non-dilutive lending, supported by AI-driven validation technology from GATC Health. This approach reduces risk for all stakeholders, accelerates funding timelines, and maximizes the chances of success for biotech startups. With nearly 100 startups already in the pipeline, this innovative funding vehicle promises to expedite therapeutic breakthroughs, benefiting investors, companies, and most importantly, patients in need.

I’m thrilled to share my executive biography, highlighting my experience in driving growth, operational excellence, and innovation within the biotech and pharmaceutical industries. From building startup companies to leading transformative clinical and operational strategies, I’ve had the privilege of contributing to life-changing advancements.

Peter Payne is a highly accomplished executive with over 30 years of leadership experience in the pharmaceutical, biotechnology, and contract research organization (CRO) industries. Known for his integrity and results-driven approach, Peter has successfully led organizations through periods of significant growth and transformation. With deep expertise in drug development, clinical trials, and corporate strategy, he has built a strong reputation for driving innovation and strategic partnerships. His leadership spans notable roles, including Vice President at Optum, President of Gennaker Bio, and CEO at multiple biotech companies. Peter’s ability to communicate complex strategies and foster cross-functional collaboration has made him a respected figure in the life sciences industry.